FDA Addresses Increased Demand and Supply of Estradiol Transdermal Patches

The FDA is actively working with all six manufacturers to increase the supply of estradiol transdermal patches, a menopausal hormone therapy, due to a significant rise in demand. This increased interest follows the FDA's November 2025 action to remove boxed warnings about certain risks from the product labeling, allowing for more individualized discussions about benefits and risks with healthcare providers.